fingolimod hydrochloride has been researched along with Choroid Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darjatmoko, SR; Farnoodian, M; Polans, AS; Sheibani, N; Song, YS; Sorenson, CM; Wang, S | 1 |
1 other study(ies) available for fingolimod hydrochloride and Choroid Neovascularization
| Article | Year |
|---|---|
Fingolimod (FTY720), a Sphinogosine-1-Phosphate Receptor Agonist, Mitigates Choroidal Endothelial Proangiogenic Properties and Choroidal Neovascularization.
Topics: Choroid; Choroidal Neovascularization; Endothelial Cells; Fingolimod Hydrochloride; Humans; Inflammation; Phosphates; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2022 |